Adverse effects of topical glucocorticosteroids

被引:761
作者
Hengge, UR
Ruzicka, T
Schwartz, RA
Cork, MJ
机构
[1] Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Dermatol, Newark, NJ 07103 USA
[3] Univ Sheffield, Sch Med, Div Genom Med, Sheffield, S Yorkshire, England
关键词
D O I
10.1016/j.jaad.2005.01.010
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Topical corticosteroids were introduced into medicine about 50 years ago. They represent a significant milestone in dermatologic therapy. Despite encouragement to report observed adverse drug reactions, the clinical practice of reporting is poor and incomplete. Likewise, adverse effects and safety of topical corticosteroids are neglected in the medical literature. The authors provide an updated review of their adverse-effect profile. Children are more prone to the development of systemic reactions to topically applied medication because of their higher ratio of total body surface area to body weight. Cutaneous adverse effects occur regularly with prolonged treatment and are dependent on the chemical nature of the drug, the vehicle, and the location of its application. The most frequent adverse effects include atrophy, striae, rosacea, perioral dermatitis, acne, and purpura. Those that occur with lower frequency include hypertrichosis, pigmentation alterations, delayed mound healing, and exacerbation of skin infections. Of particular interest is the rate of contact sensitization against corticosteroids, which is considerably higher than generally believed. Systemic reactions such as hyperglycemia, glaucoma, and adrenal insufficiency have also been reported to follow topical application. The authors provide an updated review of local and systemic adverse effects upon administration of topical corticosteroids, including the latest FDA report on the safety of such steroids in children.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 122 条
[1]   PHARMACOKINETICS OF TOPICAL HYDROCORTISONE AT PLASMA-LEVEL AFTER APPLICATIONS ONCE OR TWICE-DAILY IN PATIENTS WITH WIDESPREAD DERMATITIS [J].
AALTOKORTE, K ;
TURPEINEN, M .
BRITISH JOURNAL OF DERMATOLOGY, 1995, 133 (02) :259-263
[2]   EXTENSIVE VISUAL-LOSS WITH TOPICAL FACIAL STEROIDS [J].
AGGARWAL, RK ;
POTAMITIS, T ;
CHONG, NHV ;
GUARRO, M ;
SHAH, P ;
KHETERPAL, S .
EYE, 1993, 7 :664-666
[3]   PSEUDO-TUMOR CEREBRI [J].
AHLSKOG, JE ;
ONEILL, BP .
ANNALS OF INTERNAL MEDICINE, 1982, 97 (02) :249-256
[4]   RISKS OF UNOCCLUDED TOPICAL STEROIDS IN CLINICAL-TRIALS [J].
AKERS, WA .
ARCHIVES OF DERMATOLOGY, 1980, 116 (07) :786-788
[5]  
Ammar NM, 2000, CUTIS, V65, P69
[6]   GLUCOCORTICOIDS AND INFECTION [J].
AUCOTT, JN .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1994, 23 (03) :655-670
[7]  
AXELROD L, 1989, ANTIINFLAMMATORY STE, P377
[8]   ASSESSMENT OF SKIN PENETRATION PROPERTIES OF DIFFERENT CARRIER VEHICLES FOR TOPICALLY APPLIED CORTISOL [J].
AYRES, PJW ;
HOOPER, G .
BRITISH JOURNAL OF DERMATOLOGY, 1978, 99 (03) :307-317
[9]   CONTACT HYPERSENSITIVITY TO CORTICOSTEROIDS IN ROUTINE PATCH TEST PATIENTS - A MULTICENTER STUDY OF THE SWISS CONTACT-DERMATITIS RESEARCH GROUP [J].
BIRCHER, AJ ;
THURLIMANN, W ;
HUNZIKER, T ;
PASCHEKOO, F ;
HUNZIKER, N ;
PERRENOUD, D ;
ELSNER, P ;
SCHULTHEISS, R .
DERMATOLOGY, 1995, 191 (02) :109-114
[10]   MEDIASTINAL WIDENING IN IATROGENIC CUSHINGS SYNDROME [J].
BODMAN, SF ;
CONDEMI, JJ .
ANNALS OF INTERNAL MEDICINE, 1967, 67 (02) :399-+